BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
about
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsA comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology.Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
P2860
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
BCR-ABL isoforms associated wi ...... kinase domain point mutations?
@en
BCR-ABL isoforms associated wi ...... kinase domain point mutations?
@nl
type
label
BCR-ABL isoforms associated wi ...... kinase domain point mutations?
@en
BCR-ABL isoforms associated wi ...... kinase domain point mutations?
@nl
prefLabel
BCR-ABL isoforms associated wi ...... kinase domain point mutations?
@en
BCR-ABL isoforms associated wi ...... kinase domain point mutations?
@nl
P2093
P2860
P50
P1433
P1476
BCR-ABL isoforms associated wi ...... kinase domain point mutations?
@en
P2093
Aleksandra Silye
Franz X Gruber
Henrik Hjorth-Hansen
Kari Remes
Ole Petter Rekvig
Sakari Knuutila
Tobias Gedde-Dahl
Tuija Lundán
P2860
P2888
P304
P356
10.1007/S12032-010-9781-Z
P577
2011-01-08T00:00:00Z